Instrument Inactif

Autres langues Neuralstem, Inc. Nasdaq

Actions

US64127R3021

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

07/05	Palisade Bio, Inc. nomme Margery Fischbein à son conseil d'administration	CI
01/05	Wall Street devrait ouvrir en baisse avant la décision de la Fed sur les taux d'intérêt ; les chiffres de l'emploi privé dépassent les prévisions	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update	14/05
Palisade Bio, Inc. announced that it has received $3.999943 million in funding	10/05
Palisade Bio Appoints Margery Fischbein to its Board of Directors	07/05
Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors	07/05
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules	02/05
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts	01/05
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)	01/05
Palisade Bio?s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide	01/05
Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding	01/05
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	24/04
Palisade Bio Collaborating With Strand Life Sciences on Ulcerative Colitis Therapy	23/04
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23/04
Palisade Bio, Inc. Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach	23/04
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 in Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients Stool	17/04
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon	16/04
Palisade Bio Shows Bioactivation of PALI-2108 in Study; Shares Rise	16/04
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool	16/04
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients? Stool	16/04
Palisade Bio to Participate in the Virtual Investor Lunch Break Event	11/04
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™	10/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Neuralstem, Inc. Nasdaq

Actions

US64127R3021

Autres langues

Filtres